Cargando…

Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR

Ischemia-reperfusion (I/R) injury is a serious clinical pathology associated with acute kidney injury (AKI). Ferroptosis is non-apoptotic cell death that is known to contribute to renal I/R injury. Dexmedetomidine (Dex) has been shown to exert anti-inflammatory and organ protective effects. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Wen-hui, Shan, Xi-sheng, Zhang, Jia-xin, Liu, Hua-yue, Wang, Bi-ying, Wei, Xiang, Zhang, Mian, Peng, Ke, Ding, Jun, Xu, Shang-xian, Li, Lin-gui, Hu, Jun-kai, Meng, Xiao-wen, Ji, Fu-hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307125/
https://www.ncbi.nlm.nih.gov/pubmed/35873574
http://dx.doi.org/10.3389/fphar.2022.782466
_version_ 1784752692474675200
author Tao, Wen-hui
Shan, Xi-sheng
Zhang, Jia-xin
Liu, Hua-yue
Wang, Bi-ying
Wei, Xiang
Zhang, Mian
Peng, Ke
Ding, Jun
Xu, Shang-xian
Li, Lin-gui
Hu, Jun-kai
Meng, Xiao-wen
Ji, Fu-hai
author_facet Tao, Wen-hui
Shan, Xi-sheng
Zhang, Jia-xin
Liu, Hua-yue
Wang, Bi-ying
Wei, Xiang
Zhang, Mian
Peng, Ke
Ding, Jun
Xu, Shang-xian
Li, Lin-gui
Hu, Jun-kai
Meng, Xiao-wen
Ji, Fu-hai
author_sort Tao, Wen-hui
collection PubMed
description Ischemia-reperfusion (I/R) injury is a serious clinical pathology associated with acute kidney injury (AKI). Ferroptosis is non-apoptotic cell death that is known to contribute to renal I/R injury. Dexmedetomidine (Dex) has been shown to exert anti-inflammatory and organ protective effects. This study aimed to investigate the detailed molecular mechanism of Dex protects kidneys against I/R injury through inhibiting ferroptosis. We established the I/R-induced renal injury model in mice, and OGD/R induced HEK293T cells damage in vitro. RNA-seq analysis was performed for identifying the potential therapeutic targets. RNA-seq analysis for differentially expressed genes (DEGs) reported Acyl-CoA synthetase long-chain family member 4 (ACSL4) related to ferroptosis and inflammation in I/R mice renal, which was validated in rodent renal. Liproxstatin-1, the specific small-molecule inhibitor of ferroptosis, significantly attenuated ferroptosis-mediated renal I/R injury with decreased LPO, MDA, and LDH levels, and increased GSH level. Inhibiting the activity of ACSL4 by the Rosiglitazone (ROSI) resulted in the decreased ferroptosis and inflammation, as well as reduced renal tissue damage, with decreasing LPO, MDA and LDH level, increasing GSH level, reducing COX2 and increasing GPx4 protein expression, and suppressing the TNF-α mRNA and IL-6 mRNA levels. Dex as a α2-adrenergic receptor (α2-AR) agonist performed renal protective effects against I/R-induced injury. Our results also revealed that Dex administration mitigated tissue damage, inhibited ferroptosis, and downregulated inflammation response following renal I/R injury, which were associated with the suppression of ACSL4. In addition, ACSL4 overexpression abolishes Dex-mediated protective effects on OGD/R induced ferroptosis and inflammation in HEK293T cells, and promotion of ACSL4 expression by α2-AR inhibitor significantly reversed the effects on the protective role of Dex. This present study indicated that the Dex attenuates ferroptosis-mediated renal I/R injury and inflammation by inhibiting ACSL4 via α2-AR.
format Online
Article
Text
id pubmed-9307125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93071252022-07-23 Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR Tao, Wen-hui Shan, Xi-sheng Zhang, Jia-xin Liu, Hua-yue Wang, Bi-ying Wei, Xiang Zhang, Mian Peng, Ke Ding, Jun Xu, Shang-xian Li, Lin-gui Hu, Jun-kai Meng, Xiao-wen Ji, Fu-hai Front Pharmacol Pharmacology Ischemia-reperfusion (I/R) injury is a serious clinical pathology associated with acute kidney injury (AKI). Ferroptosis is non-apoptotic cell death that is known to contribute to renal I/R injury. Dexmedetomidine (Dex) has been shown to exert anti-inflammatory and organ protective effects. This study aimed to investigate the detailed molecular mechanism of Dex protects kidneys against I/R injury through inhibiting ferroptosis. We established the I/R-induced renal injury model in mice, and OGD/R induced HEK293T cells damage in vitro. RNA-seq analysis was performed for identifying the potential therapeutic targets. RNA-seq analysis for differentially expressed genes (DEGs) reported Acyl-CoA synthetase long-chain family member 4 (ACSL4) related to ferroptosis and inflammation in I/R mice renal, which was validated in rodent renal. Liproxstatin-1, the specific small-molecule inhibitor of ferroptosis, significantly attenuated ferroptosis-mediated renal I/R injury with decreased LPO, MDA, and LDH levels, and increased GSH level. Inhibiting the activity of ACSL4 by the Rosiglitazone (ROSI) resulted in the decreased ferroptosis and inflammation, as well as reduced renal tissue damage, with decreasing LPO, MDA and LDH level, increasing GSH level, reducing COX2 and increasing GPx4 protein expression, and suppressing the TNF-α mRNA and IL-6 mRNA levels. Dex as a α2-adrenergic receptor (α2-AR) agonist performed renal protective effects against I/R-induced injury. Our results also revealed that Dex administration mitigated tissue damage, inhibited ferroptosis, and downregulated inflammation response following renal I/R injury, which were associated with the suppression of ACSL4. In addition, ACSL4 overexpression abolishes Dex-mediated protective effects on OGD/R induced ferroptosis and inflammation in HEK293T cells, and promotion of ACSL4 expression by α2-AR inhibitor significantly reversed the effects on the protective role of Dex. This present study indicated that the Dex attenuates ferroptosis-mediated renal I/R injury and inflammation by inhibiting ACSL4 via α2-AR. Frontiers Media S.A. 2022-06-14 /pmc/articles/PMC9307125/ /pubmed/35873574 http://dx.doi.org/10.3389/fphar.2022.782466 Text en Copyright © 2022 Tao, Shan, Zhang, Liu, Wang, Wei, Zhang, Peng, Ding, Xu, Li, Hu, Meng and Ji. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tao, Wen-hui
Shan, Xi-sheng
Zhang, Jia-xin
Liu, Hua-yue
Wang, Bi-ying
Wei, Xiang
Zhang, Mian
Peng, Ke
Ding, Jun
Xu, Shang-xian
Li, Lin-gui
Hu, Jun-kai
Meng, Xiao-wen
Ji, Fu-hai
Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title_full Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title_fullStr Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title_full_unstemmed Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title_short Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR
title_sort dexmedetomidine attenuates ferroptosis-mediated renal ischemia/reperfusion injury and inflammation by inhibiting acsl4 via α2-ar
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307125/
https://www.ncbi.nlm.nih.gov/pubmed/35873574
http://dx.doi.org/10.3389/fphar.2022.782466
work_keys_str_mv AT taowenhui dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT shanxisheng dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT zhangjiaxin dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT liuhuayue dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT wangbiying dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT weixiang dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT zhangmian dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT pengke dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT dingjun dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT xushangxian dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT lilingui dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT hujunkai dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT mengxiaowen dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar
AT jifuhai dexmedetomidineattenuatesferroptosismediatedrenalischemiareperfusioninjuryandinflammationbyinhibitingacsl4viaa2ar